Type 2 diabetes among women: Clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk

Journal of Women's Health

Volumn 17, Issue 2, 2008, Pages 249-260

  Levine, Jeffrey P ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIAFORMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETHINYLESTRADIOL PLUS NORETHISTERONE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

BREAST FEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLAUDICATION; COMBINATION CHEMOTHERAPY; DIABETIC MICROANGIOPATHY; EPIDEMIC; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; TREATMENT OUTCOME; UNITED STATES; VOMITING;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SEX FACTORS; WOMEN'S HEALTH;

EID: 43049105784     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0396     Document Type: Review

References (74)

1. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. The burden of chronic diseases as causes of death, United States - Section I. 2004.
2. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125.
3. Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia 2006;49:1489.
4. Centers for Disease Control and Prevention. National diabetes fact sheet: United States, 2005: General information. Available at www.cdc.gov/diabetes/ pubs/factsheet.htm Accessed December 7, 2007.
5. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989.
6. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66.
7. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005;294:2751.
8. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387.
9. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. WISE study of women and heart disease yields important findings on frequently undiagnosed coronary syndrome. Available at www.nhlbi.nih.gov/new/press/06-01-31.htm Accessed June 12, 2006.
10. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570.
11. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73.
12. U.S. Department of Health and Human Services. National Women's Health Information Center. Office on Women's Health. Polycystic ovarian syndrome (PCOS), 2004.
13. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745.
14. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004;27(Suppl 1):S88.
15. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29(Suppl 1):S4.
16. Physicians' desk reference, 60th ed. Montvale, NJ: Thomson PDR, 2006.
17. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160.
18. Davis RA. Evolution of processes and regulators of lipoprotein synthesis: From birds to mammals. J Nutr 1997;127:795S.
19. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499.
20. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes. Diabetes Care 2001;24:1144.
21. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837.
22. Stratton IM, Adler AI, Neil HA, et al, on behalf of the U.K. Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405.
23. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643.
24. Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556.
25. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813.
26. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. JAMA 2003;290:486.
27. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract 2006;12(Suppl 1):89.
28. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care 2003;26:1485.
29. Brownlee M, Hirsch IB. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707.
30. Warren RE. The stepwise approach to the management of type 2 diabetes. Diabetes Res Clin Pract 2004;65(Suppl 1):S3.
31. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963.
32. Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005;25:244.
33. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555.
34. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003;327:951.
35. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330.
36. Vinik AI. Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus. Insulin 2006;1:2.
37. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:545.
38. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005;34:77.
39. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442.
40. Leahy JL, Cefalu WT, eds. Insulin therapy. New York: Marcel Dekker, 2002.
41. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142.
42. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006;38:172.
43. Lantus [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S., 2006.
44. Rašlová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193.
45. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269.
46. Bergenstal R, Johnson ML, Powers MA, Wynne AG, Vlajnic A, Hollander PA. Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on pre-prandial glucose patterns is a safe and effective alternative to carbohydrate counting (Carb Count) [Abstract]. Diabetes 2006;55(Suppl 1):A105.
47. Almér LO, Wollmer P, Jonson B, Almér AT. Insulin inhalation with absorption enhancer at meal-times results in almost normal postprandial insulin profiles. Clin Physiol Funct Imaging 2002;22:218.
48. Exubera [package insert]. New York: Pfizer, 2006.
49. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary 2005;40:114.
50. Brown A, Steel JM, Duncan C, Duncan A, McBain AM. An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 2004;21:604.
51. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 1999;354:1604.
52. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559.
53. Hoogwerf RJ. Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med 2006;73:477.
54. Januvia [prescribing information]. Whitehouse Station, NJ: Merck & Co., 2006.
55. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564.
56. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632.
57. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, for the Australian Carbohydrate Intolerance Study in Pregnant Women (ACH 015) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477.
58. American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004;27(Suppl 1):S76.
59. Homko CJ, Sivan E, Reece AE. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? Treat Endocrinol 2004;3:133.
60. Simmons D, Thompson CF, Conroy C, Scott DJ. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care 2001;24:2078.
61. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005;193:118.
62. Gallen IW, Jaap AJ. Insulin glargine use in pregnancy is not asociated with adverse maternal or fetal outcomes. Diabetes 2006;55(Suppl 1):A107.
63. Hod M, Visser GH, Damm P, et al. Safety and perinatal outcome in pregnancy: A randomized trial comparing insulin aspart with human insulin in 322 subjects with type 1 diabetes. Diabetes 2006;55(Suppl 1):A106 (abstract).
64. Hothersall LA, Caron E, Mullin K, Devlin JT. Insulin glargine versus NPH for managing diabetes in pregnancy. Diabetes 2006;55(Suppl 1):A107.
65. Levemir [package insert]. Princeton, NJ: Novo Nordisk, 2005.
66. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care 2005;28:1851.
67. Spencer JP, Gonzalez LS III, Barnhart DJ. Medications in the breast-feeding mother. Am Fam Physician 2001;64:119.
68. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. Diabetologia 2002;45:1509.
69. Shawe J, Lawrenson R. Hormonal contraception in women with diabetes mellitus: Special considerations. Treat Endocrinol 2003;2:321.
70. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192.
71. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, for the Health, Aging, and Body Composition (Health ABC) Study. Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349.
72. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005;289:E735.
73. Glucophage/Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2004.
74. Physicians' desk reference, 58th ed. Montvale, NJ: Thomson PDR, 2004.